Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Nephrology
Diabetes
Questions discussed in this category
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
1 Answer available
Are recurrent UTIs a contraindication to SGLT2i use?
4 Answers available
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
1 Answer available
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?
1 Answer available
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
ESPRIT Trial
1 Answer available
How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?
1 Answer available
Should GLP1 R agonists be used as first line glucose lowering agents in patients with ESKD and DM2?
1 Answer available
22567
19804
21415
22086
21179
19685
19404
Papers discussed in this category
Lancet (London, England), 2024 Jun 27
Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
N Engl J Med, 2015 Nov 09
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
Diabetes care, 2025 Jan 01
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.
Related Topics in Nephrology
Hematologic Malignancies
Radiation Oncology
Gynecologic Oncology
Genitourinary Cancers
Melanoma/Skin Cancer
Pediatric Hematology/Oncology
Prostate Cancer
Medical Oncology
Endocrine Tumors
Lymphoma